Climb Bio Inc. (NASDAQ:CLYM) is one of the best biotech penny stocks to buy according to analysts. On December 18, H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Climb Bio to $11 from $9, while maintaining a Buy rating on the shares. This sentiment was announced as the firm believes that Budoprutug’s progress across clinical tracks will culminate in the release of data readouts during 2026. The company is currently focused on two primary assets: Budoprutug, which is an anti- ...

Core Insights - Climb Bio Inc. (CLYM) is set for a data-rich year in 2026, with study results from its key programs expected to influence its strategic direction and future development phases [1] Drug Candidates - Budoprutug is an anti-CD19 monoclonal antibody designed for potent and durable B cell depletion, with both intravenous (IV) and subcutaneous (SC) administration options. It is being investigated for primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus [2] - CLYM116 is a novel anti-APRIL monoclonal antibody aimed at promoting the degradation of APRIL, targeting B-cell-mediated diseases such as systemic lupus erythematosus, myasthenia gravis, and IgA nephropathy [3] Ongoing Trials & Upcoming Catalysts - A phase 2 study named PrisMN is evaluating Budoprutug's safety and efficacy in adult subjects with primary membranous nephropathy, enrolling 45 subjects and expected to complete in 2027 [4] - A phase 1b/2a study is assessing Budoprutug in immune thrombocytopenia, with initial efficacy data anticipated in the second half of 2026 [6] - A phase 1b study is evaluating Budoprutug in systemic lupus erythematosus, with preliminary efficacy data expected in the second half of 2026 [8] - A phase 1 study for the SC formulation of Budoprutug in healthy volunteers is ongoing, with initial data expected in the first half of 2026 [10] - Regulatory clearance for a phase 1 trial of CLYM116 has been obtained, with dosing expected to start by the end of 2025 and initial data anticipated mid-2026 [10] Financial Position - As of September 30, 2025, the company reported cash, cash equivalents, and marketable securities totaling $175.8 million, which is sufficient to fund operations through 2027 [11] Company Background - Climb Bio, formerly Eliem Therapeutics, went public on August 10, 2021, under the ticker symbol "ELYM" at an IPO price of $12.50 per share. The company rebranded to Climb Bio, Inc. and changed its ticker symbol to "CLYM" on October 3, 2024, reflecting a strategic focus on immune-mediated diseases [12] - CLYM's stock has traded between $1.05 and $3.25 over the past year, closing at $3.00 on December 12, 2025, representing a 30.43% increase [13]

CLYM116 & IgAN Opportunity - Climb Bio's mission is to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases[5] - CLYM116 is an anti-APRIL monoclonal antibody being developed for IgA Nephropathy (IgAN)[8, 48] - Climb Bio has worldwide rights to CLYM116 outside Greater China, partnering with Beijing Mabworks Biotech Co, Ltd[9, 11] - Phase 1 initiation of CLYM116 is expected in Q4 2025, with initial data anticipated mid-year 2026[8, 15, 16, 106] IgAN Market & Treatment Landscape - IgAN represents a significant market opportunity estimated at ~$10-20 billion in the US, with most patients requiring lifelong treatment[12, 105] - KDIGO 2025 guidelines recommend treatment initiation for patients with proteinuria >=05 g/day, representing approximately 60-75% of patients[13] - The FDA recognizes the need for surrogate outcomes, such as improvement in proteinuria, in IgAN studies for accelerated approval[29] CLYM116 Differentiated Profile - CLYM116 is the only known "sweeper" anti-APRIL mAb in development, designed for improved activity, less frequent dosing, and a favorable safety profile[10, 57, 103, 106] - Preclinical NHP data demonstrated potential for deep and durable IgA suppression, with >70% maximal reduction after a single 6 mg/kg SC dose, and a ~2-3x longer half-life compared to sibeprenlimab[16, 74, 84, 89, 90, 104] - In NHPs, CLYM116 SC demonstrated high bioavailability of ~85% and favorable tolerability, supporting potential for convenient, at-home dosing[81]